Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Long-term safety of niraparib maintenance treatment in patients with recurrent ovarian cancer

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 1920

Lisa Marie Juden - Dana-Farber Cancer Institute, Boston, MA

Lisa Marie Juden speaks to ecancer at ONS 2019 about the long-term safety effects of niraparib in patients with recurrent ovarian cancer in the maintenance setting. 

She explains that while there were adverse events, these occurred within the first 3 months and were resolved with dose reduction. In the NOVA study, dose reductions did not have an impact on the efficacy of niraparib.

Lisa concluded that these results are important as although the NOVA trial had already reported improved PFS, these follow-up results also indicate that niraparib is safe and tolerable long-term.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation